Dennis R. Delaney’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Dennis R. Delaney’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,333	Closed	-$7K	–	60
2017 Q4	$7K	Hold	3,333	–	–	0.01%	60
2017 Q3	$7K	Hold	3,333	–	–	0.01%	50
2017 Q2	$14K	Hold	3,333	–	–	0.03%	50
2017 Q1	$23K	Hold	3,333	–	–	0.05%	51
2016 Q4	$34K	Buy	+3,333	New	+$38.1K	0.07%	52

Other funds holding MBVX

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Dennis R. Delaney's MBVX Position: Q1 2018 in Review

Dennis R. Delaney sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q1 2018, closing a stake of 3,333 shares — an estimated $7K sold.

Dennis R. Delaney first reported a position in MBVX in Q4 2016 and held it in 5 quarters. The position peaked at $34K in Q4 2016. 11 funds tracked by Wall St. Rank hold MBVX as of Q1 2018.

Dennis R. Delaney reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q1 2018 after selling out during the quarter.
Dennis R. Delaney sold 3,333 MABVAX THERAPEUTICS HLDGS INC shares in Q1 2018, an estimated $7K.
Dennis R. Delaney first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q4 2016 and held it in 5 quarters.
Dennis R. Delaney's MABVAX THERAPEUTICS HLDGS INC position peaked at $34K in Q4 2016.
11 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q1 2018.

Based on Dennis R. Delaney's 13F filing for Q1 2018, filed 24 Apr 2018.